Our novel class of highly selective small molecules are advancing in indications of neuro and cardiometabolic dysfunction. We are committed to providing a long term solution for people living with Alzheimer's, Diabetes and Obesity.   

Our once-daily oral candidate acts as a glycemic rheostat—dynamically regulating glucose while targeting the underlying biology linking metabolic dysfunction and brain health. Our data across diabetes, obesity and neurodegeneration supports a therapeutic opportunity with broad potential.

We discovered 3 novel chemistry series generating a broad genus global patent position of issuances for any disease associated with dysregulation of our multimodal target.